Teng Li Wuyun Hu Lan Jin Xianghua Yin Dongxu Kang Longzhen Piao
10.3389/fonc.2023.1164368
Front Oncol
2023 Apr 14;13:1164368.
pd-l1 anlotinib fibroblast growth factor receptor (fgfr) tislelizumab urothelial cancer (uc)
CC BY
https://pubmed.ncbi.nlm.nih.gov/37124509/
Case Reports
PMC10141313
37124509
Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases
2023